Baseline characteristics
| Studies investigating bisphosphonates on CAC progression | ||||||||||||||
| Intervention | Control | |||||||||||||
| Age (years) | Sex (% male) | HTN (%) | Diabetes (%) | Dyslipidaemia (%) | CKD (%) | Smoking (%) | Age (years) | Sex (% male) | HTN (%) | Diabetes (%) | Dyslipidaemia (%) | CKD (%) | Smoking (%) | |
| Ariyoshi et al, 20067 | 63.5±8.3 | 83.3 | – | – | – | 100 | – | 66.3±5.1 | 83.3 | – | – | – | 100 | – |
| Hill et al, 200214 | 60±10 | – | – | – | – | – | – | 62±10 | – | – | – | – | – | – |
| Nitta et al, 20048 | 63.2±8.2 | 82.9 | 100 | 23 | – | 100 | 20 | – | – | – | – | – | – | – |
| Pawade et al, 202122 | 73±8 | 80 | 75 | 22 | 43 | 7.8 | Current: 16 Former: 47 | 72±7 | 80 | 82 | 24 | 70 | 4 | Current: 6 Former: 54 |
| Studies investigating denosumab use on CAC progression | ||||||||||||||
| Chen et al, 202016 | 62.1±2.5 | 14.3 | 90.5 | 14.3 | 0 | 100 | Current: 0 Former: 9.5 | 54.8±2.0 | 42.9 | 95.2 | 9.5 | 9.5 | 100 | Current: 0 Former: 14.3 |
| Pawade et al, 202122 | 72±8 | 78 | 71 | 24 | 69 | 12 | Current: 4.1 Former: 53 | 72±7 | 80 | 82 | 24 | 70 | 4 | Current: 6 Former: 54 |
CAC, coronary artery calcification; CKD, chronic kidney disease; HTN, hypertension.